HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series.

AbstractBACKGROUND:
Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma.
OBJECTIVE:
We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate.
METHODS:
All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed.
RESULTS:
Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur.
LIMITATIONS:
The follow-up period was short, and there was no histologic confirmation of the initial diagnosis.
CONCLUSION:
IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.
AuthorsNicolas Aubut, Jimmy Alain, Joël Claveau
JournalJournal of cutaneous medicine and surgery (J Cutan Med Surg) 2012 May-Jun Vol. 16 Issue 3 Pg. 212-7 ISSN: 1203-4754 [Print] United States
PMID22713449 (Publication Type: Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Methotrexate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Injections, Intralesional
  • Male
  • Methotrexate (administration & dosage, therapeutic use)
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: